Granzyme B PET imaging inflammation and remodeling in myocardial infarction

Purpose This study aimed to evaluate whether granzyme B (GzmB)-targeted positron emission tomography (PET) imaging agent (Ga-68-grazytracer) can characterize cardiac inflammation and remodeling in myocardial infarction (MI).Methods Rats with MI were subjected to GzmB-targeted PET/CT on post-operative days 1, 3, 6, 14, and 28. Autoradiography, Masson staining, immunohistochemistry, and ELISA were performed to verify the inflammatory response and remodeling after MI in vitro. Rats were treated with GzmB inhibitor Z-IETD-FMK to improve cardiac remodeling. Cardiac function tests were performed by echocardiography at 6 weeks after MI.Results The highest uptake of Ga-68-grazytracer was observed on day 3 after MI compared with the values obtained on the other days (0.294 +/- 0.03% ID/g at 3 days vs. 0.122 +/- 0.01% ID/g in the sham group, P < 0.001). Immunohistochemistry showed significantly high expression of GzmB and CD8, in line with the PET/CT imaging results. Autoradiography revealed 68 Ga-grazytracer accumulation in the infarcted myocardium. The 68 Ga-grazytracer uptake of treated rats was significantly reduced compared with that in the MI groups (0.184 +/- 0.03%ID/g vs. 0.286 +/- 0.03%ID/g; P < 0.001). Echocardiography showed that the left ventricular ejection fraction was lower in the MI groups than in the ischemia reperfusion group. GzmB inhibitor treatment was shown to be effective in improving cardiac function without significantly shortening infarct size.Conclusions This study demonstrated the potential of Ga-68-grazytracer imaging to delineate adverse inflammatory responses and pathological cardiac remodeling, which can help predict heart function. PET/CT imaging-guided therapy may reduce myocardial injury and improve heart function in MI.